

# Review of: "[Research Note] Unveiling the Interplay of Klotho Protein, Chemotherapy-Induced Klotho Protein Deficiency, and the Pivotal Role of GLP-1 Agonists like Ozempic in Cancer Survivorship Patient Survival Rate after Chemotherapy Treatment"

A. L. Zakharenko<sup>1</sup>

<sup>1</sup> Institute of Chemical Biology and Fundamental Medicine

Potential competing interests: No potential competing interests to declare.

The article is devoted to the very interesting topic of improving the condition of cancer patients with the help of well-known GLP-1 agonist drugs such as Ozempic. The rationale for the effectiveness of their use for this purpose is to increase the expression level of Klotho, a protein important for aging and longevity. However, the article needs improvement.

The harm from various chemotherapy drugs is described in a very drawn-out manner, and very little is said about Klotho. Nothing at all is said about the specific role of Klotho in the kidneys. It is clear that they will suffer along with other organs; it is unclear why the authors singled out the kidneys. Lots of unnecessary repetitions in the text.

Part of the text about Ozempic is written much better, with more detail about the mechanism of action of semaglutide, and more coherently in general. However, the interaction of GLP-1 agonists and Klotho is very poorly described.

Overall, it is unclear what the purpose of the review is. If the goal is to propose the use of GLP-1 agonists to improve the condition of cancer patients, and the rationale is to increase the expression of Klotho, then one should write in more detail about what is known on this topic.